Bayer | Pharmaceuticals

Innovation powered by people We are leveraging our longstanding expertise in cardiology and are innovating in precision cardiology to broaden solutions for patients living with challenging conditions such as heart failure, chronic kidney disease or stroke. Meet our Bayer principal scientists Peter Kolkhof and Stefan Heitmeier to learn more about the importance of applied science in driving positive change in patient outcomes. Watch the full video here 👇 http://spr.ly/6040jRoij

Check out the following article based on a recent interview of our Vividion Therapeutics, Inc.'s CEO Aleksandra Rizo as part of InVivo's Rising Leaders 2024 series. It highlights how Vividion is fueling Bayer's pipeline by continuing to leverage the biotech entrepreneurial spirit and global pharma resources in the race to bring meaningful medicines to patients. https://lnkd.in/e5Z3qRia

This issue of #120Months is a very special one. This time, I am not the author of the article myself, but have invited my two colleagues Sebastian Guth (Chief Operating Officer Bayer Pharmaceuticals and President of Bayer USA) and Dr. Claus Runge (Global Head of Market Access, Public Affairs & Sustainability at Bayer Pharmaceuticals) as guest authors. Both are among the architects of our new Global Health Unit. With this unit we want to improve healthcare access for underserved people in low- and middle-income countries. You will learn more about how we intend to achieve this in this edition of 120 Months. As we have just launched the Global Health Unit, this issue of 120 Months is not being published at the end of the month as usual; nonetheless, we have rarely been so up to date! In any case, I would like to thank my two guest authors very much for contributing a 120 Months article - I know how much work it is, and it is a great pleasure to be able to recommend it! 

5 de MAYO: DIA MUNDIAL DE LA HIPERTENSIÓN PULMONAR Como desde hace 12 años, en este día conmemoramos la Hipertensión Pulmonar (HP), un grupo heterogéneo de enfermedades caracterizadas por su alto impacto en la calidad de vida de las personas, e invitamos a recordar el esfuerzo que todos los actores del sistema de salud debemos realizar para lograr tanto el diagnóstico como el adecuado tratamiento de los pacientes que la sufren. La HP es un grupo heterogéneo de enfermedades caracterizadas por el aumento de la presión en la circulación pulmonar, que produce cansancio y falta de aire progresivos, y que pueden terminar en la muerte. En Bayer trabajamos desde hace más de 20 años en el desarrollo de opciones terapéuticas para estos pacientes. El equipo de HP de Pharma Cono Sur los invita a recordar que trabajamos en una compañía comprometida con la innovación y la salud de la población. #pacientes, #hipertensionpulmonar, #HP, #terapiainhalada #bayer #programadepacientes

🌍 Calling Europe-based biotech founders and scientists with start-up ambitions in #celltherapy, #genetherapy and #oncology! 🌍   Are you exploring how incubation can accelerate your research and path to success?   Join our webinar with Cellbricks CEO and Bayer Co.Lab alumnus, Alexander Leutner, to discover first-hand insights, practical advice, and Q&As about transforming your venture via an incubation program.   Register now: https://lnkd.in/e-m_dM5A   #BayerCoLab #TeamBayer

Aaron Blankenship is one of our product owners in R&D. Together with his colleagues he organizes a complex ecosystem of data and digital platforms. Meet him and find out why dancing became an important part of his career. 👇 #DataScienceRockstars #TeamBayer #InnovationInHealthcare #DataScience

+++ #news +++ Bayer and Evotec will further join forces and focus their research collaboration on precision #cardiology. The joint effort aims to develop innovative precision treatments for cardiovascular diseases. Learn more: http://spr.ly/6045j87U3 #TeamBayer

+++ #NEWS +++ Bayer is committed in advancing novel options in #Ophthalmology that address unmet needs for patients with retinal diseases, their carers and healthcare professionals. The #ARVO Annual Meeting addresses how vision research is continually being transformed. Learn More: http://spr.ly/6042b7zhq Bayer | Ophthalmology

In healthcare, true innovation lies in the impact we have on patients' lives. At Bayer, our collaboration with industry pioneers Asklepios BioPharmaceutical, Inc. (AskBio), Viralgen Vector Core, and TAAV Biomanufacturing Solutions has propelled us to the forefront of gene therapy manufacturing—a testament to our commitment to turning potential into reality. Viralgen has delivered over 1100 batches of AAV-based gene therapies since 2018. This is more than a number—it's a reflection of the dedication of our >400-strong team in San Sebastian, who come to work each day with one goal in mind: making a positive impact on patient care. As we continue to advance in this field, we're not just chasing innovation; we're advancing hope for patients around the world. #TeamBayer

+++ Pipeline #News +++ Fast Track Designation for Heart Failure Gene Therapy Asklepios BioPharmaceutical, Inc. (AskBio)'s gene therapy program for congestive heart failure has been granted U.S. FDA Fast Track Designation, emphasizing the need to rapidly advance new therapeutic modalities such as gene therapy for people living with congestive heart failure. Learn more: https://lnkd.in/ekY-krjA #TeamBayer